Lu X, Horner JW, Paul E, Shang X, Troncoso P, Deng P, Jiang S, Chang Q, Spring DJ, Sharma P et al (2017) Effective combina- torial immunotherapy for castration-resistant prostate cancer. Nature 543:728-732Lu X, et al. (2017) Effective combinatorial immunotherapy for castration-...
Taken together, although prostate cancer is generally believed to be a tumor unresponsive to PD-1 inhibition, careful dissection of tumor biology is able to provide an approach toward predictive biomarkers that has the potential for expanded clinical utility. Key Points: Biomarkers for anti-PD1 and...
Management of men with metastatic castration-resistant prostate cancer following potent androgen receptor inhibition: a review of novel investigational therapies Introduction Prostate cancer (PCa) is the second most common cancer, and it is the fifth leading cause of cancer-related death among men.1The...
MMR, mismatch repair; MSI, microsatellite instability; mCRPC, metastatic castration-resistant prostate cancer. Author’s contribution Study concept and design: Wei Xue, Theo M. de Reijke and Kenneth J. Pienta. Data acquisition: Liang Dong and Richard C. Zieren. Data analysis: Liang Dong and ...
A systematic review of the literature from 2020 to 2022 was conducted by the CCAFU on the elements of therapeutic management of metastatic and castration-resistant prostate cancer (PC), while evaluating the references and their levels of evidence. Results Androgen deprivation therapy (ADT) remains ...
A significant fraction of patients with advanced prostate cancer treated with androgen deprivation therapy experience relapse with relentless progression to lethal metastatic castration-resistant prostate cancer (mCRPC). Immune checkpoint blockade using antibodies against cytotoxic-T-lymphocyte-associated protein ...
ADT is currently the standard treatment for patients with recurrent or metastatic prostate cancer, aiming to eliminate circulating androgens that fuel prostate cancer growth; however, most patients eventually develop castration-resistant prostate cancer, which is associated with a worse prognosis [7, 10,...
Castration resistant prostate cancer DDR: DNA damage response EMT: Epithelial-to-mesenchymal transition ENO2: Neuron-specific enolase 2 H3K4me2/3: Di−/tri-methylated histone H3 lysine 4 H3K9me1/2: Mono−/di-methylated histone H3 lysine 9 ...
(androgen deprivation therapy) has been a mainstay of treatment for advanced disease. However, metastatic prostate cancer inevitably develops resistance to androgen deprivation therapy and enters a stage called metastatic castration-resistant prostate cancer (mCRPC). mCRPC is currently incurable and is ...
ARTICLE https://doi.org/10.1038/s41467-020-18649-5 OPEN Abiraterone acetate preferentially enriches for the gut commensal Akkermansia muciniphila in castrate-resistant prostate cancer patients Brendan A. Daisley 1,2,3, Ryan M. Chanyi 1,2,3, Kamilah Abdur-Rashid1,2,3, Kait F. Al 1,2,3,...